Boston Biomedical reports detailed data from Phase III gastric cancer trial of napabucasin

The Boston Biomedical Inc. unit of Sumitomo Dainippon Pharma Co. Ltd. (Tokyo:4506) reported data from the Phase III BRIGHTER trial in 714 patients with previously treated advanced gastric or gastroesophageal junction cancer showing that second-line treatment with twice-daily 480 mg oral napabucasin (BBI608) plus paclitaxel led to a median overall (OS), the primary endpoint, of 6.93 months vs. 7.36 months for paclitaxel alone (HR=1.01, 95% CI: 0.86, 1.2, p=0.8596). The data were released in an abstract ahead of the American Society of Clinical Oncology (ASCO) meeting in Chicago.

Last year, Boston Biomedical said an interim analysis by a DSMB showed that napabucasin plus paclitaxel was unlikely to meet the primary endpoint in the double-blind, international trial (see BioCentury, July 7, 2017)...